A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Study Overview

• Status: Active, not recruiting
• Conditions: Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer
• Intervention / Treatment: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: JNJ-56021927

Detailed Description

This is a multicenter, open-label (participants will know the identity of study drug received) study in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC). The study is a single sequence design (ie, all participants will take abiraterone acetate + prednisone [AAP] once daily on Days 1-7 of Treatment Cycle 1 and then proceed with combined daily intake of AAP+JNJ-56021927 from Treatment Cycle 1, Day 8 through to the end of treatment [ie, for up to an expected duration of approximately 18 months] and will be conducted as two cohorts (group of participant's). The study will consist of a 28-day screening phase to determine eligibility, an open-label treatment phase consisting of 28-day treatment cycles, and a 30-day follow-up phase for collection of adverse events (AE) after last dose of study drug. Participants will have blood samples collected during the study to evaluate pharmacokinetics, safety, and antitumor activity (PSA). Participant safety will also be monitored by the collection of adverse events. Imaging assessments for disease evaluation will be planned at discretion of the Investigator. Once all participants have completed study treatment up to Cycle 3 Day 1, a data cutoff is planned to evaluate the short term safety profile of the combination and to complete the PK analysis up to the cutoff date. All participants will continue on study (ie, to receive treatment) until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. The end of the study is defined when all participants have completed treatment. Participant's safety will be monitored throughout the study.

• Study Type: Interventional
• Enrollment (Actual): 57
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada
  • Quebec
    • Montreal, Quebec, Canada
• Netherlands
  • Rotterdam, Netherlands
• United Kingdom
  • Sutton, United Kingdom
• United States
  • California
    • Los Angeles, California, United States
    • San Francisco, California, United States
  • Texas
    • Houston, Texas, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (<=) 2
• Histologically or cytologically confirmed adenocarcinoma of the prostate
• Documentation of metastatic disease
• Prostate cancer progression
• Surgically or medically castrated, with testosterone levels of less than (<) 50 nanogram per deciliter (ng/dL)
• Adequate bone marrow and organ function

Exclusion Criteria:

• Known brain metastases
• Pathological finding consistent with small cell carcinoma of the prostate
• Administration of an investigational agent within 4 weeks of Treatment Cycle 1, Day 1
• Chemotherapy, or immunotherapy for the treatment of prostate cancer within 4 weeks of Treatment Cycle 1, Day 1
• Therapies that must be discontinued or substituted prior to Treatment Cycle 1, Day 1 include the following: Medications known to lower the seizure threshold; Herbal and non-herbal products that may decrease prostate specific antigen (PSA) levels (that is, saw palmetto, pomegranates or pomegranate juice); Medications known to induce drug metabolizing enzymes such as dexamethasone, rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's wort, etc.; and, potent inhibitors of CYP3A4 or CYP2C8

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1; Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.	Drug: Abiraterone Acetate; Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).; Other Names: ZYTIGA; Drug: Prednisone; Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).; Drug: JNJ-56021927; Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Experimental: Cohort 2; Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.	Drug: Abiraterone Acetate; Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).; Other Names: ZYTIGA; Drug: Prednisone; Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).; Drug: JNJ-56021927; Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24]) of abiraterone	The AUC (0-24) is area under the plasma concentration-time curve from time zero to time 24 hours.	Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)
Maximum plasma concentration (Cmax) of abiraterone, prednisone and its metabolite prednisolone	The Cmax is the maximum observed plasma concentration.	Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)
Area Under the Plasma Concentration-time Curve From Time Zero to Time 12 Hours (AUC [0-12]) of prednisone and its metabolite prednisolone	The AUC (0-12) is area under the plasma concentration-time curve from time zero to time 12 hours.	Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Plasma Concentration Curve (AUC [0- 24h]) of JNJ-56021927 and its metabolite JNJ-56142060	The AUC (0-24) is area under the plasma concentration-time curve from time zero to time 24 hours.	Day 36 (Treatment Cycle 2), on Day 57 (Treatment Cycle 3)
Maximum plasma concentration (Cmax) of JNJ-56021927 and its metabolite JNJ-56142060	The Cmax is the maximum observed plasma concentration.	Day 36 (Treatment Cycle 2), on Day 57 (Treatment Cycle 3)
Change in prostate specific antigen (PSA)	Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland.	Up to the end of the treatment phase (approximately 18 months)
Maximal decline in prostate specific antigen (PSA)	Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland.	Up to the end of the treatment phase (approximately 18 months)

Collaborators and Investigators

• Sponsor: Aragon Pharmaceuticals, Inc.
• Investigators: Study Director: Aragon Pharmaceuticals, Inc. Clinical Trial, Aragon Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 9, 2014
• Primary Completion (Actual): June 27, 2016
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: April 21, 2014
• First Submitted That Met QC Criteria: April 24, 2014
• First Posted (Estimated): April 28, 2014

Study Record Updates

• Last Update Posted (Actual): June 5, 2026
• Last Update Submitted That Met QC Criteria: June 4, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Prostate cancer; Prednisone; Prostatic Neoplasms; JNJ-56021927; Metastatic Castration-Resistant Prostate Cancer (mCRPC); Abiraterone Acetate (ZYTIGA)
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Neoplasms; Polycyclic Compounds; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Pregnadienediols; Androstenes; Androstanes; Abiraterone Acetate; Prednisone
• Other Study ID Numbers: CR104358; 56021927PCR1010 (Other Identifier: Janssen Research & Development, LLC); 2014-001426-14 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: No